Primary Care POC Diagnostics Market Report 2025

This Primary Care POC Diagnostics market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The primary care POC diagnostics market size has grown strongly in recent years. It will grow from $16.46 billion in 2024 to $17.78 billion in 2025 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to the increasing prevalence of chronic diseases, shift towards personalized medicine, growing healthcare expenditure, rise in supportive regulatory frameworks and expedited approval processes, and growing emphasis on early disease detection and prevention strategies.

The primary care POC diagnostics market size is expected to see strong growth in the next few years. It will grow to $23.86 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to the emergence of infectious disease outbreaks, expanding applications in non-communicable diseases, increasing adoption in home healthcare settings, growth in precision medicine initiatives, rising healthcare infrastructure investments, increasing disease burden, and growing awareness of the importance of early disease detection. Major trends in the forecast period include the integration of artificial intelligence (AI) and machine learning algorithms, advancements in molecular diagnostics technologies, miniaturization and portability of POC diagnostic devices, integration of smart devices, and usage of multiplexing and panel testing in POC diagnostics.

The anticipated increase in infectious diseases is poised to drive the expansion of the primary care POC diagnostics market in the foreseeable future. Infectious diseases, caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, spread through direct or indirect contact with contaminated surfaces, air, water, or vectors such as insects. Factors contributing to their prevalence include poor environmental conditions, urbanization, antimicrobial resistance, and insufficient vaccination coverage. Primary care POC diagnostics play a crucial role in addressing this rise in infectious diseases by enabling early detection, timely treatment, and effective disease control across various healthcare settings. For example, in October 2023, a report from the UK Health Security Agency revealed a 22% increase in HIV diagnoses in England from 3,118 in 2021 to 3,805 in 2022. Additionally, in November 2023, the World Health Organization reported approximately 10.6 million cases of tuberculosis globally in 2022, affecting millions across different demographics. Thus, the surge in infectious diseases is propelling the primary care POC diagnostics market forward.

Leading companies in the primary care POC diagnostics market are concentrating on advanced technological solutions, such as portable point-of-care RT-PCR systems, to optimize their market revenue. These systems, designed for real-time reverse transcription polymerase chain reaction (RT-PCR) tests outside traditional laboratories, offer mobility and compactness. For instance, Genes2Me Pvt. Ltd. introduced the Rapi-Q Point of Care RT PCR solution in October 2022, featuring an eight-well block design with four fluorescent channels, claimed to deliver rapid results in under 45 minutes. Portable and lightweight, the Rapi-Q system is suitable for various settings such as hospitals, blood banks, health clinics, research laboratories, and airports. It boasts high sensitivity, accuracy, and performance in disease detection, compatible with over 50 lyophilized, room-temperature disease detection kits.

In July 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical company, acquired LumiraDx's point-of-care technology from LumiraDx for $350 million. With this acquisition, Roche aims to expand its diagnostic portfolio and enhance access to decentralized testing, particularly in primary care settings and low- to middle-income countries. LumiraDx is a UK-based point-of-care diagnostic company focused on transforming community-based healthcare.

Major companies operating in the primary care POC diagnostics market are Hoffmann-La Roche Ltd, Abbott Laboratories, Siemens Healthineers AG, Becton, Dickinson And Company, bioMerieux SA, Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., Nova Biomedical Corporation, Randox Laboratories Ltd, Ortho Clinical Diagnostics, Nipro Corporation, OraSure Technologies, Meridian Bioscience Inc, DiaSorin SpA, Sekisui Diagnostics LLC, EKF Diagnostics Holdings plc, Trinity Biotech plc, Fujirebio Diagnostics Inc., Immunodiagnostic Systems Holdings PLC, Quotient Limited, AccuBioTech Co. Ltd., bioMedomics Inc.

North America was the largest region in the primary care POC diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary care POC diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the primary care POC diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A point-of-care (POC) diagnostic in primary care entails conducting medical tests or evaluations conveniently and swiftly within a primary care environment, such as a doctor's office or clinic, without the need for specialized equipment or extensive laboratory processing. These diagnostics aim to deliver prompt results, enabling healthcare providers to make timely decisions regarding patient care during the initial consultation.

Primary care POC diagnostics encompass a range of products, including glucose monitoring, cardiometabolic testing products, infectious disease testing products, coagulation testing products, pregnancy and fertility testing products, tumor or cancer marker testing products, cholesterol testing products, hematology testing products, drug-of-abuse (DOA) testing products, among others. Glucose monitoring involves measuring blood glucose levels to manage diabetes and is available in different types such as prescription-based and over-the-counter (OTC) testing. These are utilized across various settings, including hospitals, diagnostic centers, research laboratories, home-care settings, and others.

The primary care POC diagnostics market research report is one of a series of new reports that provides primary care POC diagnostics market statistics, including primary care POC diagnostics industry global market size, regional shares, competitors with a primary care POC diagnostics market share, detailed primary care POC diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the primary care POC diagnostics industry. This primary care POC diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The primary care POC diagnostics market consists of sales of respiratory pathogen testing products, thyroid function testing products, electrolyte testing products, and liver function testing products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.